Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.51 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
32 33 Next >
These 5 growth stocks are now in buy ranges
Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs. 
Via MarketBeat
Topics ETFs
Where Will CRISPR Therapeutics Be in 5 Years?
The company could maintain the momentum it gained last year. 
Via The Motley Fool
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
Despite A bump in the road, the biotech's future looks sunny. 
Via The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
CRISPR Therapeutics shares have soared 39% over the past three months. 
Via The Motley Fool
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
Has investing in Vertex been a better option than just putting your money in the S&P 500? 
Via The Motley Fool
Topics Stocks
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase. 
Via Investor's Business Daily
Topics ETFs
Could Editas Medicine Become the Next CRISPR Therapeutics?
The similarities between the pair are striking, but it might not be enough. 
Via The Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026
Discover the trailblazing strategies of three tech stocks that are reshaping industries through innovation, adaptability and revenue surges. 
Via InvestorPlace
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
Via Benzinga
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
Via Benzinga
Topics ETFs
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
Via Investor's Business Daily
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
These risky stocks can deliver big returns for investors. 
Via The Motley Fool
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
Key regulatory developments sent this biotech stock higher. 
Via The Motley Fool
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
An acquisition could be both a blessing and a curse for long-term investors. 
Via The Motley Fool
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
My 3 Highest-Conviction Growth Stocks to Buy in 2024
Simply put, these stocks inspire confidence. 
Via The Motley Fool
My 5 Top Growth Stocks to Buy Hand Over Fist for 2024
2024 could be a year of growth. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
3 Cathie Wood Stocks to Start Off Your New Year Right
The following stocks could deliver big gains over time. 
Via The Motley Fool
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
The Ultimate Growth Stock to Buy With $1,000 Right Now
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024
You'll find exciting innovators across industries. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS